Antisense nucleic acid compound targeted to VEGF
US6150092A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 23, 1996 |
| Grant date | Nov 21, 2000 |
| Priority date | — |
| Expiry date | Dec 23, 2016 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/475
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to an antisense nucleic acid compound which has a nucleotide sequence complementary to at least 8 contiguous nucleotides in the nucleotide sequence of a gene coding for a vascular endothelial growth factor and which inhibits the expression of the vascular endothelial growth factor, as well as to a therapeutic or diagnostic agent for cancers, rheumatoid arthritis, diabetes etc., comprising said antisense nucleic acid as active ingredient. Further, the present invention relates to a method of preventing the expression of the vascular endothelial growth factor, comprising use of an antisense nucleic acid compound which has a nucleotide sequence complementary to at least 8 contiguous nucleotides in the nucleotide sequence of a gene coding for a vascular endothelial growth factor and which inhibits the expression of the vascular endothelial growth factor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.